Resmini M, Gul S, Carter S, Sonkaria S, Topham C M, Gallacher G, Brocklehurst K
Laboratory of Structural and Mechanistic Enzymology, Department of Molecular and Cellular Biology, Queen Mary and Westfield College, University of London, Mile End Road, London E1 4NS, U.K.
Biochem J. 2000 Feb 15;346 Pt 1(Pt 1):117-25.
A potentially general kinetic method for the investigation of active-site availability in preparations of macromolecular catalysts was developed. Three kinetic models were considered: (a) the conventional two-step model of enzyme catalysis, where the preparation contains only active catalyst (E(a)) and inert (i.e. non-binding, non-catalytic) material (E(i)); (b) an extension of the conventional model (a) involving only E(a) and E(i), but with non-productive binding to E(a) (in addition to productive binding); (c) a model in which the preparation contains also binding but non-catalytic material (E(b)), predicted to be present in polyclonal catalytic antibody preparations. The method involves comparing the parameters V(max) and K(m) obtained under catalytic conditions where substrate concentrations greatly exceed catalyst concentration with those (klim/obs, the limiting value of the first-order rate constant, k(obs), at saturating concentrations of catalyst; and Kapp/m) for single-turnover kinetics, in which the reverse situation obtains. The active-site contents of systems that adhere to model (a) or extensions that also lack E(b), such as the non-productive binding model (b), may be calculated using E(a)=V(max)/klim/obs. This was validated by showing that, for alpha-chymotrypsin, identical values of E(a) were obtained by the kinetic method using Suc-Ala-Ala-Pro-Phe-4-nitroanilide as substrate and the well-known 'all-or-none' spectroscopic assay using N-trans-cinnamoylimidazole as titrant. For systems that contain E(b), such as polyclonal catalytic antibody preparations, V(max)/klim/obs is more complex, but provides an upper limit to E(a). Use of the kinetic method to investigate PCA 271-22, a polyclonal catalytic antibody preparation obtained from the antiserum of sheep 271 in week 22 of the immunization protocol, established that E(a) is less than approx. 8% of [IgG], and probably less than approx. 1% of [IgG].
开发了一种潜在的通用动力学方法,用于研究大分子催化剂制剂中活性位点的可用性。考虑了三种动力学模型:(a) 酶催化的传统两步模型,其中制剂仅包含活性催化剂 (E(a)) 和惰性(即不结合、无催化作用)物质 (E(i));(b) 传统模型 (a) 的扩展,仅涉及 E(a) 和 E(i),但存在与 E(a) 的非生产性结合(除了生产性结合);(c) 一种模型,其中制剂还包含结合但无催化作用的物质 (E(b)),预计存在于多克隆催化抗体制剂中。该方法涉及将在底物浓度大大超过催化剂浓度的催化条件下获得的参数V(max)和K(m)与单周转动力学中的参数(klim/obs,在催化剂饱和浓度下一级速率常数k(obs)的极限值;以及Kapp/m)进行比较,在单周转动力学中情况相反。符合模型 (a) 或也缺乏 E(b) 的扩展模型(如非生产性结合模型 (b))的系统的活性位点含量可以使用E(a)=V(max)/klim/obs来计算。通过表明对于α-胰凝乳蛋白酶,使用Suc-Ala-Ala-Pro-Phe-4-硝基苯胺作为底物的动力学方法和使用N-反式肉桂酰咪唑作为滴定剂的著名“全或无”光谱测定法获得了相同的E(a)值,对此进行了验证。对于包含 E(b) 的系统,如多克隆催化抗体制剂,V(max)/klim/obs更复杂,但提供了E(a)的上限。使用动力学方法研究PCA 271-22,这是一种在免疫方案第22周从绵羊271的抗血清中获得的多克隆催化抗体制剂,确定E(a)小于约[IgG]的8%,可能小于约[IgG]的1%。